Nautilus Biotechnology

While technology advances were perhaps less dramatic than in the year prior, several firms teased future releases that could have significant impacts.

According to the company, its research into organoids and mouse models of Alzheimer's disease has resulted in the detection of roughly 800 proteoforms of the protein tau.

The company, which posted a net loss of $16.4 million in Q3, cited a high failure rate for candidate affinity probes used by the platform.